0001246360-19-000765.txt : 20190225
0001246360-19-000765.hdr.sgml : 20190225
20190225174911
ACCESSION NUMBER: 0001246360-19-000765
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190221
FILED AS OF DATE: 20190225
DATE AS OF CHANGE: 20190225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Swan Winifred L
CENTRAL INDEX KEY: 0001341405
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51567
FILM NUMBER: 19630815
MAIL ADDRESS:
STREET 1: NXSTAGE MEDICAL INC
STREET 2: 439 SOUTH UNION STREET 5TH FLOOR
CITY: LAWRENCE
STATE: MA
ZIP: 01843
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NxStage Medical, Inc.
CENTRAL INDEX KEY: 0001333170
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 043454702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 MERRIMACK STREET
CITY: LAWRENCE
STATE: MA
ZIP: 01843
BUSINESS PHONE: 978-687-4700
MAIL ADDRESS:
STREET 1: 350 MERRIMACK STREET
CITY: LAWRENCE
STATE: MA
ZIP: 01843
4
1
form.xml
PRIMARY DOCUMENT
X0306
4
2019-02-21
true
0001333170
NxStage Medical, Inc.
NXTM
0001341405
Swan Winifred L
350 MERRIMACK STREET
LAWRENCE
MA
01843
false
true
false
false
SVP and General Counsel
Common Stock
2019-02-21
4
D
false
13077
30
D
0
D
Stock Option (Right to Buy)
11.03
2019-02-21
4
D
false
11542
0
D
2013-04-04
2023-03-03
Common Stock
11542
0
D
Stock Option (Right to Buy)
14.66
2019-02-21
4
D
false
49529
0
D
2014-04-10
2024-03-09
Common Stock
49529
0
D
Stock Option (Right to Buy)
16.66
2019-02-21
4
D
false
53315
0
D
2015-04-03
2025-03-02
Common Stock
53315
0
D
Stock Option (Right to Buy)
15.58
2019-02-21
4
D
false
71509
0
D
2016-04-09
2026-03-08
Common Stock
71509
0
D
Stock Option (Right to Buy)
27.89
2019-02-21
4
D
false
39884
0
D
2017-04-09
2027-03-08
Common Stock
39884
0
D
Restricted Stock Unit
0
2019-02-21
4
D
false
9314
0
D
2018-03-09
2020-03-09
Common Stock
13971
0
D
Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash.
This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price.
These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share.
/s/ Aras Lapinskas, attorney-in-fact for Winifred Swan
2019-02-25